New cancer drug enters human testing: could help tumors with specific genetic changes

NCT ID NCT05932862

Recruiting now Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

Summary

This is the first human study of an experimental cancer drug called XL309. Researchers are testing it alone and combined with another cancer drug (olaparib) in 429 patients with advanced solid tumors that have stopped responding to standard treatments. The main goals are to determine safe doses, see how the body processes the drug, and look for early signs that it might help control cancer growth.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Exelixis Clinical Site #1
RECRUITING

Houston, Texas, 77030, United States
Exelixis Clinical Site #10
WITHDRAWN

Kansas City, Missouri, 64111, United States
Exelixis Clinical Site #11
RECRUITING

Germantown, Tennessee, 38138, United States
Exelixis Clinical Site #12
WITHDRAWN

Fountain Valley, California, 92708, United States
Exelixis Clinical Site #13
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
Exelixis Clinical Site #14
RECRUITING

Rochester, Minnesota, 55905, United States
Exelixis Clinical Site #15
RECRUITING

Jacksonville, Florida, 32224, United States
Exelixis Clinical Site #16
RECRUITING

Tampa, Florida, 33612, United States
Exelixis Clinical Site #2
WITHDRAWN

Houston, Texas, 77030, United States
Exelixis Clinical Site #3
RECRUITING

San Antonio, Texas, 78229, United States
Exelixis Clinical Site #4
RECRUITING

Austin, Texas, 78758, United States
Exelixis Clinical Site #5
RECRUITING

New York, New York, 10029, United States
Exelixis Clinical Site #6
RECRUITING

Nashville, Tennessee, 37203, United States
Exelixis Clinical Site #7
RECRUITING

Cleveland, Ohio, 44106, United States
Exelixis Clinical Site #8
RECRUITING

Orlando, Florida, 32827, United States
Exelixis Clinical Site #9
RECRUITING

New Brunswick, New Jersey, 08901, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR